United States — Ekhbary News Agency
A recent study from Northwestern University reveals a mounting financial burden associated with popular weight-loss drugs like Ozempic and Wegovy. This escalating cost, a hidden consequence of their success, threatens to destabilize public budgets and private insurance premiums across the United States. The research, published in the 'Journal of the American Heart Association,' meticulously tracks the financial evolution of these therapies between 2017 and 2022, highlighting a shift from a purely clinical phenomenon to a significant macroeconomic challenge.
Escalating Costs and Patient Spending Paradox
The study found a staggering 157% increase in the total average cost per user for adults taking GLP-1 receptor agonists solely for obesity reduction, without a diabetes diagnosis, over five years. This surge aligns with regulatory approvals: semaglutide (Ozempic) for type 2 diabetes in 2017, and for weight management (Wegovy) in 2021. Consequently, GLP-1 drug usage soared by 230% among diabetic patients and an astounding 643% in non-diabetic individuals. Curiously, while the overall drug bill climbed, direct out-of-pocket patient expenses actually decreased by 26% for non-diabetics and 39% for those with diabetes.
Read Also
- LeBron James Hints at NBA Future Decision at Fanatics Fest
- Sarri Unveiled at Atalanta, Reflects on Lazio Past and Future Ambitions
- Paula Badosa Reflects on Tough Tennis Career, Daughter's Future
- AC Milan and MSC Cruises Extend Partnership, Connecting Milan to the World
- Roddick Slams Shelton, Fritz, Tiafoe for Grand Slam Underperformance
Broader Societal Impact and Sustainability Concerns
This reduction in direct patient cost, however, merely shifts the financial load onto healthcare systems and intermediaries. Dr. Michael Hammond, the lead author and an internal medicine resident at Northwestern University's McGaw Medical Center, warns that these escalating costs will ultimately affect everyone, regardless of whether they use the treatments. "The high total costs of GLP-1 drugs could end up causing an increase in taxes and an increase in health insurance premiums, both for people who take these medications and for those who don't," Hammond stated. The popularity of these medications, designed for long-term use, has ignited a crucial debate over their long-term coverage viability, especially as monthly prescriptions often exceed a thousand dollars per patient in mixed or private health systems. As it happens, insurers and employers in the US are already implementing drastic measures to curb the financial drain.
